Hepatitis Therapeutics Market Size, Share & Industry Analysis, By Indication (Hepatitis B {Nucleoside Analogues, Nucleotide Analogues, Interferons, and Others}, Hepatitis C {NS5A Inhibitors, NS5B Polymerase Inhibitors, Protease Inhibitors (NS3/4A), and Others}, Hepatitis D {Entry Inhibitors, Prenylation Inhibitors, and Interferons}, and Others), By Age Group (Adults and Pediatrics), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies & Others), and Regional Forecast, 2026-2034